CNS Pharmaceuticals Inc. (CNSP)
NASDAQ · Healthcare
CNS Pharmaceuticals Inc. Shareholder Equity 2020–2025
CNS Pharmaceuticals Inc. annual shareholder equity history from 2020 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- CNS Pharmaceuticals Inc. shareholder equity as of December 31, 2025: 4.5M, a 26.78% decrease year-over-year.
- CNS Pharmaceuticals Inc. shareholder equity for 2025 were 4.5M, a 26.78% decrease from 2024.
- CNS Pharmaceuticals Inc. shareholder equity for 2024 were 6.2M, a 239.36% decrease from 2023.
- CNS Pharmaceuticals Inc. shareholder equity for 2023 were -4.4M, a 154.50% decrease from 2022.
- CNS Pharmaceuticals Inc. shareholder equity for 2022 were 8.1M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| CNS Pharmaceuticals Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $5 |
| 2024 | $6 |
| 2023 | $-4 |
| 2022 | $8 |
| 2021 | $6 |
| 2020 | $14 |
CNS Pharmaceuticals Inc. Shareholder Equity — FAQ
CNS Pharmaceuticals Inc. (CNSP) shareholder equity over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CNSP's shareholder equity history?
The chart and table above show CNS Pharmaceuticals Inc.'s shareholder equity by year and by quarter, including the growth rate.